

China Biologic Products, Inc.  
Form 8-K  
February 25, 2016

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest event Reported): February 22, 2016

**CHINA BIOLOGIC PRODUCTS, INC.**

*(Exact name of registrant as specified in its charter)*

**Delaware**                                      **001-34566**                                      **75-2308816**  
*(State or other jurisdiction of (Commission File No.) (IRS Employer ID No.)  
incorporation or organization)*

**18th Floor, Jialong International Building  
19 Chaoyang Park Road  
Chaoyang District, Beijing 100125  
People's Republic of China**  
*(Address of Principal Executive Offices)*

**86-10-6598-3111**

*Registrant's telephone number, including area code*

---

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

**ITEM 1.01 Entry into a Material Definitive Agreement.**

On February 22, 2016, China Biologic Products, Inc. (the “Company”) entered into an amended and restated director agreement (the “Amended Director Agreement”) with Mr. David Li, which amended and restated the director agreement entered into between the Company and Mr. David Li on November 7, 2013 to update Mr. David Li’s compensation arrangements. Under the Amended Director Agreement, Mr. David Li will be (1) paid a monthly fee of \$5,000 as compensation for his services as a director of the Company, and (2) awarded 5,000 shares of the Company’s restricted stock under the Company’s 2008 Equity Incentive Plan, which will vest in two equal portions over a 24-month period with the first portion vesting on February 23, 2017 and the second on February 23, 2018.

The foregoing description of the Amended Director Agreement is qualified in its entirety by reference to the full text of the Amended Director Agreement, attached hereto as Exhibit 10.1 and incorporated herein by reference.

**ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.**

On February 25, 2016, the Company issued a press release announcing its financial results for its fiscal year ended December 31, 2015. A copy of the press release, which the Company is furnishing to the Securities and Exchange Commission, is attached as Exhibit 99.1 and incorporated by reference herein.

**ITEM 7.01 REGULATION FD DISCLOSURE.**

The information set forth in Item 2.02 above is incorporated by reference herein.

The information set forth in Item 2.02 and Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

**Exhibit Number Description**

|      |   |
|------|---|
| 10.1 | Amended and Restated Director Agreement dated February 22, 2016 by and between the Company and Mr. David Li |
| 99.1 | Press release dated February 25, 2016   |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 25, 2016 CHINA BIOLOGIC  
PRODUCTS, INC.

By: /s/ David (Xiaoying) Gao  
David (Xiaoying) Gao  
Chief Executive Officer